Efficacy and Safety of ABBV-154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo-Controlled Trial

Journal:

Arthritis & Rheumatology

Published:

2025-09-01

DOI:

10.1002/art.43266

Affiliations:

10

Authors:

14

Go to article

Institutions	Authors	Share
AbbVie, United States of America (USA)	7.000000	0.50
SouthWest Arthritis Research Group, United States of America (USA)	1.000000	0.07
Altoona Center for Clinical Research, United States of America (USA)	1.000000	0.07
Csolnoky Ferenc Hospital, Hungary	1.000000	0.07
Kochi Medical School Hospital, Japan	1.000000	0.07
Hospital Universitario Virgen de Valme, Spain	1.000000	0.07
Charité - University Medicine Berlin, Germany	0.500000	0.04
German Rheumatism Research Centre Berlin (DRFZ), Germany	0.500000	0.04
Chaim Sheba Medical Center at Tel HaShomer, Israel	0.500000	0.04
Tel Aviv University (TAU), Israel	0.500000	0.04

Interested in Clinical Sciences?